Introduction
Compared with other categories of drugs, such as antibiotics and nonsteroidal antiinflammatory agents, antiepileptic drugs (AEDs) are associated with a high incidence of cutaneous adverse drug reactions (cADRs). 1 cADRs impose a large burden on healthcare systems, including increased treatment costs, patient pain or loss of work time, 2 and often limit the use of AED therapy. The most common cADR is a benign exanthematous eruption, which manifests as a mild and monosymptomatic maculopapulous exanthema that resolves when the AED associated with the reaction is withdrawn. 1 Severe life-threatening reactions can also occur, such as Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) and drug hypersensitivity syndrome. 1, 2 The development of a rash in association with the use of two or more AEDs is known as cross-reactivity to AEDs, which is a formidable clinical problem. 3 In a study involving a Chinese population of patients with epilepsy, cross-reactivity between aromatic AEDs occurred in 13.14% of patients who had previously experienced cADRs in association with at least one AED, and in 3.65% of patients who had experienced cADRs in association with at least three AEDs. 4 Studies have suggested a strong 5 -7 Following these studies, the US Food and Drug Administration updated the CBZ label to include genetic information on the HLA-B*1502 allele, and recommended genetic screening for the HLA-B*1502 allele in all patients of Asian ethnicity with epilepsy, before starting CBZ therapy. 8 This genetic advance led to increasing scientific interest among researchers to examine whether the other aromatic AEDs were also associated with cross-reactivity patterns in patients positive for the HLA-B*1502 allele. The genetic link with AED cross-reactivity has rarely been reported, however. Here, two cases of cross-reactivity patterns following AED administration in individuals of Han Chinese ethnicity, who tested positive for the HLA-B*1502 allele, are described.
Case reports CASE 1
A 61-year-old female presented to the outpatient clinic at Putuo Central Hospital, Shanghai, China, in February 2005 after she started to experience seizures two to four times every month. Her seizures were characterized as complex partial seizures. Initially she was treated with CBZ 200 mg twice a day, orally. The dosage was increased to 200 mg three times daily, orally, 1 week later. On day 10 of CBZ treatment, the patient developed erythematous skin rashes, which were initially located on the thigh and were followed by widespread itching and a maculopapular rash on the trunk and limbs. There was no fever or jaundice.
At 12 days after initial treatment, routine laboratory investigations in this patient revealed a leucocyte count of 6.8 × 10 9 cells/l with 3.6% eosinophils. Liver and kidney function tests and serum electrolyte levels were normal. CBZ was immediately discontinued and the maculopapular eruption cleared within 1 week. The patient's clinical manifestations did not meet the criteria of SJS and were diagnosed by a dermatologist as benign cutaneous drug-related eruptions.
The patient experienced another episode of tonic-clonic seizures in March 2010; 2 days after the re-experience of seizure, valproate 500 mg twice daily was administered orally. Due to inadequate epilepsy control, oxcarbamazepine (OXC) 900 mg/day orally was added to the patient's regimen in May 2010. Unfortunately, 2 weeks after starting OXC treatment, the patient developed a skin reaction similar to the one that first occurred in February 2005, and OXC was withdrawn immediately. The patient recovered from the skin reaction 5 days later, although she experienced 14 seizures in the following 5 months.
In November 2010, when the woman was 66 years old, she presented to the epilepsy outpatient clinic at Huashan Hospital, Fudan University, Shanghai, China. Her treatment was reviewed and levetiracetam (1000 mg/day, orally) was added to her valproate therapy. As of the time of publication, she has remained seizure free for 13 months.
Approval for HLA genotyping was obtained from the Huashan Hospital Ethics Committee and written consent was obtained from the patient. Genomic DNA from peripheral blood lymphocytes was extracted from 1 ml of blood, according to established protocols, using the TIANamp Blood Genomic DNA Purification Kit (Tiangen Biotechnology Co. Ltd, Beijing, China), following the manufacturer's instructions.
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sequencing-based typing (PCR-SBT). All primers were synthesized by Jierui Biotechnology Co. Ltd (Shanghai, China). The DNA sequence for primer design was downloaded from the National Center for Biotechnology Information website (http://www.ncbi.nlm.nih.gov). The primers for PCR were as follows: forward, 5′-AGACCCTCGACCGGCGAGAGC-3′; reverse, 5′-AAGGGAGGGCGACATTCTAG-3′.
The PCR was carried out using a thermal cycler: from Dongsheng Biotech Co. Ltd (Shanghai, China) in a 50 µl volume, including: 1 µl genomic DNA, 5 µl 10 × buffer, 5 µl magnesium chloride, 1 µl 10 mM dNTP mix, 1.5 µl primer mix at a 10 pM dilution each, 0.6 µl Taq polymerase (5 U/µl) (all from Fermentas, Vilnius, Lithuania) and 35.4 µl water. The cycling programme involved preliminary denaturation at 94°C for 2 min, followed by 35 cycles of denaturation at 94°C for 20 s, annealing at 56°C for 20 s, and elongation at 72°C for 40 s, with a final elongation step of 72°C for 3 min. The PCR products were purified and sequenced by Jierui Biotechnology Co. Ltd. The results showed the presence of the HLA-B*1502 allele in this patient.
CASE 2
A female with no family history of epilepsy began to experience episodes of disturbance of consciousness and stereotyped violent generalized shaking in August 1999, when she was 15 years old. She developed complex partial seizures every 2 -3 months when she was 20 years old. She had received no treatment until she came to the outpatient clinic of Jiaxing People's Hospital, Jiaxing, Zhejiang, China, in March 2004. Physical examination was unremarkable. Her electroencephalography (EEG) showed bilateral epileptiform discharges with a normal computed tomography scan.
Anticonvulsant therapy with phenytoin (PHT) 100 mg/day orally was started immediately. The patient developed infected eyes, sore throat, itching over the whole body and an erythematous rash over her chest and proximal upper limbs 10 days later. This was followed by a high fever (39.1°C), oral ulcers and maculopapule rashes with a toxic appearance over the whole body, within 24 h.
Laboratory investigations showed leucocytosis (white blood cells 12.8 × 10 9 cells/l; reference value 4 -10 × 10 9 cells/l). Although PHT was discontinued, the patient's condition deteriorated. The following day, blisters were observed on the patient's thigh. According to the toxic rash, blisters and other clinical features described above, SJS was diagnosed by an experienced dermatologist. After oral steroid and antihistamine treatment (the drug name, dose and dosing schedule are unknown) for 1 week, the patient's cADRs improved. She was discharged from hospital 10 days later in a good general condition and switched to phenobarbital (PB) 90 mg/day, orally. A maculopapular eruption over the upper limbs developed 2 weeks later, from which the patient recovered 3 days after PB was discontinued. During this period, her repeat EEG showed right temporal discharges, and brain magnetic resonance imaging analysis displayed mild atrophy of the head of the right hippocampus. Two weeks later, CBZ 100 mg three times daily was administered orally and, after a further 2 weeks, the dose was increased to 300 mg twice daily. The patient developed a reaction similar to that observed after the introduction of PB; she recovered from this reaction by taking oral antihistamines (the drug name, dose and dosing schedule are unknown) and discontinuing CBZ. At 2 weeks after the patient recovered from cADRs, topiramate 75 mg twice daily was administered, orally.
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Following this and as of the time of publication, the patient experienced three complex partial seizures once in 13 months and no generalized tonic-clonic seizures.
Written consent was obtained from the Huashan Hospital Ethics Committee, Shanghai, China. HLA-B genotyping for this patient was carried out by PCR-SBT as described for case 1 and the patient was shown to be positive for HLA-B*1502.
Discussion
Since a Taiwanese study demonstrated that 44 Han Chinese patients with CBZ-induced SJS were all positive for the HLA-B*1502 allele, 5 research has focused on whether genetic associations can be found in other ethnic groups in whom cADRs have been induced by various AEDs. Some studies have demonstrated that aromatic AED-induced SJS/TEN (referring mainly to CBZ and PHT) share a common risk allele -HLA-B*1502in Asian patient populations. 1, 6, 9, 10 Others have failed to show significant associations between AED-induced cADRs and the HLA-B*1502 allele, even in Asian patient populations. 11 -14 The majority of studies concluded that the HLA-B*1502 allele is associated with severe cADRs such as AEDinduced SJS/TEN, 1,6,9,10 but could not find an association between this allele and benign maculopapular exanthema. 7, 15 Only one case-control study has found four among nine cases of OXC-induced mild maculopapular eruption to be positive for the HLA-B*1502 allele among patients of Han Chinese ethnicity. 16 Thus, studies investigating the associations between AEDinduced cADRs with HLA-B*1502 allele positivity have yielded inconsistent results.
The present study reported cross-reactivity to AEDs (CBZ and OXC, PHT, PB and CBZ) in two female Han Chinese patients who tested positive for the HLA-B*1502 allele. One patient had benign maculopapular exanthema; the other had SJS. Such findings are rare. Consequently, we propose that the HLA-B*1502 allele may be associated with a pattern of cADRs in response to crossreactivity to AEDs. If this hypothesis could be confirmed in larger studies, it may help to explain the previous inconsistent conclusions.
Patients who develop cADRs in association with one drug may develop another episode of cADRs when switched to other drugs with similar chemical structures. 4 This crossreactivity has been observed in patients receiving AEDs. 4 Furthermore, cADRs are most commonly encountered in patients treated with aromatic AEDs. 1, 16 A retrospective study in a Chinese population of patients with epilepsy showed that crossreactivity among aromatic AEDs -including CBZ, valproic acid, PHT, PB, clonazepam, OXC, lamotrigine, gabapentin and topiramate -occurred in 13.14% of patients who had previously experienced cADRs in association with at least one AED, and in 3.65% of patients who had experienced cADRs in association with at least three AEDs. 4 In addition, 66.67% of patients with OXC-induced cADRs reacted to CBZ, 40% of patients with CBZ-induced cADRs reacted to OXC, 52.94% of patients with CBZ-induced cADRs reacted to PHT, and 69.23% of patients with PHT-induced cADRs reacted to CBZ. 4 No genotyping of HLA-B*1502 was mentioned in this study. 4 The present study suggests that the HLA-B*1502 allele is associated with a cross-reactivity pattern of cADRs from AEDs (CBZ and OXC, PHT, PB and CBZ). Consequently, before another AED is introduced, we recommend that the presence of the HLA-B*1502 allele be tested for any patient with cross-reactivity to AEDs. Administration of another aromatic AED should be avoided in patients who develop cADRs following use of a first aromatic AED;
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Carbamazepine, PHT and PB are metabolized to form arene oxide metabolites by hepatic cytochrome P450 enzymes. 3 Findings from in vitro studies have challenged the classic 'hapten hypothesis' by demonstrating that the parent drugs (hapten) CBZ, PHT, and PB may stimulate T-cell clones, even in the absence of any apparent reactive metabolite formation. 4 The oxidation of CBZ to 10,11-epoxide is regarded as the most common cause of sideeffects, while OXC is a 10-keto analogue of CBZ. The pathogenesis of such idiosyncratic effects appears to be complex. T-cell lymphocyte clones may react to these drugs, to their metabolites, to similarly structured substances or to proteins modified by them or by their metabolites. 17 In addition, it has been proposed that the HLA-B*1502 allele codes for a molecule that is displayed on the surface of antigen-presenting cells. 18 Based on these mechanisms, the patients in whom cross-reactivity to more than one AED occurred may have had a higher frequency of HLA-B*1502 allele positivity than the patients experiencing cADRs in association with single AEDs. There were only two patients in the present case report. These findings require further confirmation in larger studies.
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